The intensity of joint pain in relation to changes in serum TNFα during therapy with anti-TNFα inhibitors.

Circulating TNFα levels did not decrease in RA patients treated with TNFα inhibitors, despite clinical and biochemical improvement. It is possible, that circulating TNFα is responsible for the persistence of joint pain in this group of patients.